logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Timothy Fitzgerald

Johnson and Johnson
H指数:13
被引数:687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

从其他先进疗法转换为 guselkumab、肿瘤坏死因子抑制剂、白细胞介素-17 抑制剂或 apremilast 后的银屑病标签内持续性

Journal of Dermatological Treatment
IF3.9
2026-02-240
OA
Maryia Zhdanava; Timothy Fitzgerald; Porpong Boonmak; Dominic Pilon; Samuel Schwartzbein; Béatrice Libchaber; Steven R. Feldman
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

真实世界研究中，在24个月内比较起始使用Guselkumab或皮下注射白介素-17A抑制剂治疗银屑病关节炎患者的标签内治疗持续性。

Advances in Therapy
IF4
2025-11-210
OAAI
Philip J. Mease; Jessica A. Walsh; Timothy P. Fitzgerald; Soumya D. Chakravarty; Elizabeth Adamson; Bruno Emond; Carmine Rossi; Samuel Schwartzbein; Kana Yokoji; Yuxi Wang; Patrick Lefebvre; Dominic Pilon; Shikha Singla; Joseph F. Merola
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

24个月内活动性银屑病关节炎患者使用古塞库单抗或皮下肿瘤坏死因子抑制剂的标签内治疗持续性

Rheumatology and Therapy
IF2.9
2025-11-140
OAAI
Philip J. Mease; Jessica A. Walsh; Timothy P. Fitzgerald; Soumya D. Chakravarty; Elizabeth Adamson; Bruno Emond; Carmine Rossi; Samuel Schwartzbein; Kana Yokoji; Yuxi Wang; Patrick Lefebvre; Dominic Pilon; Shikha Singla; Joseph F. Merola
WORK-ABLE SOLUTIONS: PRELIMINARY REPORT ON THE IDENTIFICATION AND NEED FOR AN INTEGRATED CARE OCCUPATIONAL THERAPY WORK INTERVENTION FOR INDIVIDUALS WITH MUSCULOSKELETAL DISORDERS AND ARTHRITIS

可行方案：关于为患有肌肉骨骼疾病和关节炎的个体识别并确定开展整合性护理职业治疗工作干预的初步报告

ANNALS OF THE RHEUMATIC DISEASES
IF20.6
2024-06-010
PRE
Codd, Y.; Fitzgerald, T.; Brownlee, J.; Mahon, K.; Stapleton, T.; Glennon, O.; Killeen, G.; Kane, D.
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

CorEvitas银屑病登记处中重度斑块型银屑病患者接受Guselkumab治疗9-12个月的真实疗效

DERMATOLOGY AND THERAPY
IF4.2
2022-12-312
OAAI
Armstrong, April W. W.; Fitzgerald, Timothy; McLean, Robert R. R.; Teeple, Amanda; Uy, Jonathan P. P.; Olurinde, Mobolaji; Rowland, Katelyn; Guo, Lin; Shan, Ying; Duffin, Kristina Callis

研究方向

暂未获取到该数据
A
Amanda Teeple
H 指数:12论文数:86被引数:544
P
Patrick Lefèbvre
H 指数:51论文数:804被引数:1.0万
M
Maryia Zhdanava
H 指数:15论文数:124被引数:1,049
K
Katelyn Rowland
H 指数:5论文数:39被引数:148
R
Robert R. McLean
H 指数:41论文数:169被引数:9,395
J
Jessica A. Walsh
H 指数:28论文数:172被引数:3,187
S
Soumya D. Chakravarty
H 指数:24论文数:126被引数:2,544
D
Dominic Pilon
H 指数:22论文数:279被引数:2,502
K
Kristina Callis Duffin
H 指数:47论文数:202被引数:8,943
H 指数:0论文数:47被引数:658